Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Allergy and Clinical Immunology Unit, Center for the Diagnosis and Treatment of Osteoporosis, AUSL 04 64100 Teramo, Italy.
Int J Mol Sci. 2020 Feb 13;21(4):1239. doi: 10.3390/ijms21041239.
The study of the immunoskeletal interface has led to the discovery of numerous cytokines involved in the regulation of bone remodeling, providing valuable information on the pathogenesis of osteoporosis. The role of inflammatory cytokines of the Th1 and Th17 profile in osteoporosis is well known. Here we focus on two newly discovered Th2 cytokines, IL-31 and IL-33, whose implications in osteoporosis are recently emerging. Clinical and experimental observations suggest an important role of the IL-33/IL-31 axis in osteoporosis. IL-33 induces IL-31 secretion by Th2 cells and inhibits RANKL-dependent osteoclastogenesis, thus counteracting bone loss. IL-31 influences Th1/Th17 osteoclastogenetic inflammation and limits Th2 osteoprotective processes, thus favoring osteoporosis. Better knowledge of the role of IL-31 and IL-33 and their receptor complexes in osteoporosis could provide an interesting perspective for the development of new and more effective therapies, possibly with less side effects.
免疫骨骼界面的研究导致了许多细胞因子的发现,这些细胞因子参与了骨重塑的调节,为骨质疏松症的发病机制提供了有价值的信息。Th1 和 Th17 细胞因子在骨质疏松症中的作用是众所周知的。在这里,我们专注于两种新发现的 Th2 细胞因子,IL-31 和 IL-33,它们在骨质疏松症中的作用最近才出现。临床和实验观察表明,IL-33/IL-31 轴在骨质疏松症中起着重要作用。IL-33 诱导 Th2 细胞分泌 IL-31,并抑制 RANKL 依赖性破骨细胞生成,从而对抗骨质流失。IL-31 影响 Th1/Th17 破骨细胞生成性炎症,并限制 Th2 护骨过程,从而有利于骨质疏松症。更好地了解 IL-31 和 IL-33 及其受体复合物在骨质疏松症中的作用,可能为开发新的、更有效的治疗方法提供一个有趣的视角,这些方法可能副作用更小。